Epinephrine/Adrenaline Alginate Film
Anaphylaxis
Pre-clinical/DevelopmentActive
Key Facts
About Klaria
Klaria is a private, clinical-stage biotech company pioneering a disruptive transmucosal drug delivery platform. Its core technology is an alginate-based film that adheres to the oral mucosa, delivering active pharmaceutical ingredients directly into the bloodstream, bypassing the gastrointestinal tract and first-pass metabolism. The company's strategy focuses on reformulating injectable drugs with poor oral bioavailability into convenient, patient-friendly films, with lead programs in migraine (sumatriptan) and anaphylaxis (epinephrine). Klaria aims to create superior, lower-cost products that can capture significant market share in multi-billion dollar therapeutic areas.
View full company profileTherapeutic Areas
Other Anaphylaxis Drugs
| Drug | Company | Phase |
|---|---|---|
| Nasefrin | Noveeda | Preclinical |
| Epinephrine Auto-Injector | Viatris | Filed |
| SYMJEPI | Assertio Holdings | Approved |